Literature DB >> 33606139

A Simple Emergency Department-Based Score Predicts Complex Hospitalization in Patients with Inflammatory Bowel Disease.

Abhishek Verma1, Sanskriti Varma2, Daniel E Freedberg3, Jordan E Axelrad4.   

Abstract

BACKGROUND AND AIMS: Thirty percent of inflammatory bowel disease (IBD) patients hospitalized with flare require salvage therapy or surgery. Additionally, 40% experience length of stay (LOS) > 7 days. No emergency department (ED)-based indices exist to predict these adverse outcomes at admission for IBD flare. We examined whether clinical, laboratory, and endoscopic markers at presentation predicted prolonged LOS, inpatient colectomy, or salvage therapy in IBD patients admitted with flare.
METHODS: Patients with ulcerative colitis (UC) or colonic involvement of Crohn's disease (CD) hospitalized with flare and tested for Clostridioides difficile infection (CDI) between 2010 and 2020 at two urban academic centers were studied. The primary outcome was complex hospitalization, defined as: LOS > 7 days, inpatient colectomy, or inpatient infliximab or cyclosporine. A nested k-fold cross-validation identified predictive factors of complex hospitalization.
RESULTS: Of 164 IBD admissions, 34% (56) were complex. Predictive factors included: tachycardia in ED triage (odds ratio [OR] 3.35; confidence interval [CI] 1.79-4.91), hypotension in ED triage (3.45; 1.79-5.11), hypoalbuminemia at presentation (2.54; 1.15-3.93), CDI (2.62; 1.02-4.22), and endoscopic colitis (4.75; 1.75-5.15). An ED presentation score utilizing tachycardia and hypoalbuminemia predicted complex hospitalization (area under curve 0.744; CI 0.671-0.816). Forty-four of 48 (91.7%) patients with a presentation score of 0 (heart rate < 99 and albumin ≥ 3.4 g/dL) had noncomplex hospitalization.
CONCLUSIONS: Over 90% of IBD patients hospitalized with flare with an ED presentation score of 0 did not require salvage therapy, inpatient colectomy, or experience prolonged LOS. A simple ED-based score may provide prognosis at a juncture of uncertainty in patient care.
© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC part of Springer Nature.

Entities:  

Keywords:  Colectomy; Inflammatory bowel disease; Infliximab; Length of stay; Predictive score

Mesh:

Substances:

Year:  2021        PMID: 33606139      PMCID: PMC8373997          DOI: 10.1007/s10620-021-06877-8

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  30 in total

1.  Cortisone in ulcerative colitis; final report on a therapeutic trial.

Authors:  S C TRUELOVE; L J WITTS
Journal:  Br Med J       Date:  1955-10-29

2.  Rising hospitalization rates for inflammatory bowel disease in the United States between 1998 and 2004.

Authors:  Geoffrey C Nguyen; Anne Tuskey; Themistocles Dassopoulos; Mary L Harris; Steven R Brant
Journal:  Inflamm Bowel Dis       Date:  2007-12       Impact factor: 5.325

Review 3.  Response to corticosteroids in severe ulcerative colitis: a systematic review of the literature and a meta-regression.

Authors:  Dan Turner; Catharine M Walsh; A Hillary Steinhart; Anne M Griffiths
Journal:  Clin Gastroenterol Hepatol       Date:  2006-12-04       Impact factor: 11.382

4.  Trends in hospitalization rates for inflammatory bowel disease in the United States.

Authors:  Meenakshi Bewtra; Chinyu Su; James D Lewis
Journal:  Clin Gastroenterol Hepatol       Date:  2007-03-26       Impact factor: 11.382

5.  Predicting outcome in severe ulcerative colitis.

Authors:  S P Travis; J M Farrant; C Ricketts; D J Nolan; N M Mortensen; M G Kettlewell; D P Jewell
Journal:  Gut       Date:  1996-06       Impact factor: 23.059

6.  Predicting the outcome of severe ulcerative colitis: development of a novel risk score to aid early selection of patients for second-line medical therapy or surgery.

Authors:  G T Ho; C Mowat; C J R Goddard; J M Fennell; N B Shah; R J Prescott; J Satsangi
Journal:  Aliment Pharmacol Ther       Date:  2004-05-15       Impact factor: 8.171

7.  Rising prevalence of venous thromboembolism and its impact on mortality among hospitalized inflammatory bowel disease patients.

Authors:  Geoffrey C Nguyen; Justina Sam
Journal:  Am J Gastroenterol       Date:  2008-08-05       Impact factor: 10.864

8.  Colectomy rate in acute severe ulcerative colitis in the infliximab era.

Authors:  A Aratari; C Papi; V Clemente; A Moretti; R Luchetti; M Koch; L Capurso; R Caprilli
Journal:  Dig Liver Dis       Date:  2008-05-09       Impact factor: 4.088

9.  Impact of Clostridium difficile on inflammatory bowel disease.

Authors:  Mazen Issa; Aravind Vijayapal; Mary Beth Graham; Dawn B Beaulieu; Mary F Otterson; Sarah Lundeen; Susan Skaros; Lydia R Weber; Richard A Komorowski; Josh F Knox; Jeanne Emmons; Jasmohan S Bajaj; David G Binion
Journal:  Clin Gastroenterol Hepatol       Date:  2007-03       Impact factor: 11.382

10.  The direct and indirect cost burden of Crohn's disease and ulcerative colitis.

Authors:  Teresa B Gibson; Eliza Ng; Ronald J Ozminkowski; Shaohung Wang; Wayne N Burton; Ron Z Goetzel; Ross Maclean
Journal:  J Occup Environ Med       Date:  2008-11       Impact factor: 2.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.